Ethics Finance Marketing Pharmaceuticals 
Marshall Goldsmith
FEBRUARY 8, 2018
Deepa Prahalad – Focused on design and emerging markets. Telisa Yancy – Chief Marketing Officer at American Family Insurance. Darek Lenart – Senior VP HR, Finance MasterCard. Former HR director with Pepsi Central Eastern Europe, and gained HR expertise at PLIVA Pharmaceutical Company (now part of Teva Group).
Harvard Business Review
JUNE 8, 2015
Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products. Experimentation is vital.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Harvard Business Review
MARCH 24, 2011
Competitors whispered that Gupta was committing the most un-McKinsey-like of sins: cutting price to get into new markets. As the stock market began to take off, though, and options rained down on corporate execs, the compensation tables began to turn, certainly for the top ranks. And what risks did he run? At the very least, contagion.
Harvard Business Review
JANUARY 10, 2013
initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. The most notable was Fannie Mae's $10.8 billion restatement. In another instance, a new enforcement. The largest payments were from Pfizer ($2.3 billion) and GlaxoSmithKline ($3 billion).
Harvard Business Review
SEPTEMBER 19, 2016
This logic and the institutions that reinforce it, like competitive markets and the rule of law, have transformed the world and lifted billions of people from poverty. Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. How should you make this decision?
Expert insights. Personalized for you.
70 
Let's personalize your content